Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC

Conditions:   Head and Neck Squamous Cell Carcinoma;   Neoadjuvant Therapy Interventions:   Drug: 3cycles (Toripalimab + cetuximab);   Procedure: Surgery;   Radiation: Radiotherapy or chemoradiotherapy Sponsor:   Wuhan Union Hospital, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials